Keywords: |
cancer chemotherapy; treatment outcome; disease-free survival; unclassified drug; overall survival; clinical trial; drug tolerability; paresthesia; doxorubicin; drug efficacy; side effect; treatment duration; drug approval; note; paclitaxel; research design; follow-up studies; progression free survival; quality of life; breast cancer; epidermal growth factor receptor 2; antineoplastic agents, phytogenic; maintenance therapy; randomized controlled trials as topic; breast neoplasms; docetaxel; survival time; clinical trials, phase iii as topic; disease progression; drug response; neoplasm metastasis; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; taxane derivative; trastuzumab; antibiotics, antineoplastic; anthracycline; clinical trials, phase ii as topic; hand foot syndrome; heart left ventricle ejection fraction; congestive heart failure; multicenter studies as topic; liposomes; polyethylene glycols; antimetabolite; bsi 201; drug choice; cross-over studies
|